Whalesbook
Apollo Hospitals ka Q4 FY26 Result ekdum zabardast!
Bade bhai, Apollo Hospitals Enterprise ne Q4 FY26 ke liye jo results diye hain woh dekhne laayak hain. Unka consolidated revenue pichle saal ke comparison mein 18% badhkar aaya hai. Is growth mein sabse bada haath unke hospital division ka hai, jisne 16% zyada revenue generate kiya, matlab ₹3,270 Crore. Patients se jo average revenue milta hai, woh bhi 9.2% badha hai.
Aur haan, pharmacy business bhi peeche nahi raha! Iska revenue 20% badhkar ₹2,850 Crore ho gaya. Naye stores khulne ki planning aur achi offline sales ne isko boost diya hai. Company ne high-margin services jaise CTVS (Cardio Thoracic and Vascular Surgery) par bhi focus kiya hai, jismein 22% zyada procedures hue, jisne profit ko aur improve kiya hai. Jab result aaye, toh shares mein bhi thodi tez activity dikhi, jisse pata chalta hai ki investors ka interest bana hua hai.
Aage Kya Plan Hai?
Analysts predict kar rahe hain ki hospital business mein 16% ka CAGR growth dekha ja sakta hai FY26 se FY28 tak. Iska reason hai 1,400 naye hospital beds jo FY28 tak add hone wale hain, jisme se 900 toh FY27 mein hi start ho jayenge. Pharmacy business bhi 18% CAGR se grow karega, har saal lagbhag 600 naye stores khulenge, aur same-store sales bhi mid-teen growth dikhayegi.
Shuru mein jab naye hospitals start honge toh thoda margin pressure aa sakta hai FY27 mein, par FY28 tak group EBITDA margins 100 basis points badhkar 16% ho jayenge. Yeh improvement naye hospitals ke ramp-up, specialized services ke badhte contribution aur online pharmacy ke profit se hoga.
Kya Kuch Challenges Bhi Hain?
Sab acha hone ke baad bhi kuch cheezein hain jin par dhyan dena padega. 1,400 naye beds add karne mein kaafi paisa lagega, toh short-term cash flow par pressure aa sakta hai aur margin kam ho sakta hai. Healthcare sector mein competition bhi kaafi hai, Fortis Healthcare aur Max Healthcare jaise players bhi badh rahe hain. Pharmacy business ko bhi naye rivals ke saath compete karne ke liye innovate karna padega.
Analysts ne March 2027 ke liye target price ₹9,444 set kiya hai. Lekin agar execution mein koi problem aayi ya costs badh gayi, toh projections par asar pad sakta hai.
Analysts Ka Bharosa
Analysts ne Apollo Hospitals par apna 'Long' rating phir se confirm kiya hai. Company ke growth plans aur operational efficiency ko dekh kar woh kaafi confident hain. EBITDA margins ka 16% tak jaana aur hospital & pharmacy business mein steady growth dekh kar yeh ₹9,444 ka target feasible lag raha hai. Valuation ke liye hospital aur pharmacy business ko alag-alag multiples se evaluate kiya gaya hai, jo company ke future potential par bharosa dikhata hai.